Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jody Neer

Neurology Goshen, IN Medical Doctor

NPI 1720085210 CMS profile 213813

2832 Elkhart Rd, Goshen, IN 46526

Open in the dashboard

General payments

$3,112

141 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jody Neer of Goshen, IN is reported in the CMS Open Payments database as having received $3,112 across 141 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $561 25
2024 General $526 15
2023 General $508 15
2022 General $210 5
2021 General $131 8
2020 General $339 19
2019 General $838 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jody Neer
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Jody Neer were reported at $561. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Jody Neer Neurology median Middle half National median
2019 $838 $474 $118–$2,177 $163
2020 $339 $367 $82–$2,309 $114
2021 $131 $438 $104–$2,547 $132
2022 $210 $442 $103–$2,388 $149
2023 $508 $464 $119–$2,312 $160
2024 $526 $468 $119–$2,323 $164
2025 $561 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $499 24 payments
  2. UCB, Inc. $275 8 payments
  3. Biogen, Inc. $248 10 payments
  4. Supernus Pharmaceuticals, Inc. $208 14 payments
  5. Novartis Pharmaceuticals Corporation $192 11 payments
  6. Neurelis, Inc. $168 2 payments
  7. Catalyst Pharmaceuticals, Inc. $122 1 payment
  8. Jazz Pharmaceuticals Inc. $119 1 payment
  9. Eisai Inc. $103 6 payments
  10. Allergan Inc. $75 5 payments
  11. Other $1,103 59 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,997 136 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $61 3 payments
  3. Education $54 2 payments
Products named General payments · program years 2019–2025
  1. Briviact $245 6 payments
  2. VYALEV $226 6 payments
  3. TROKENDI XR $184 13 payments
  4. VALTOCO $168 2 payments
  5. VUMERITY $141 4 payments
  6. UBRELVY $129 10 payments
  7. FYCOMPA $122 1 payment
  8. Epidiolex $119 1 payment
  9. MAYZENT $108 5 payments
  10. QULIPTA $88 8 payments
  11. Other $1,882 106 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

1,303

Median for Neurology: 833

Drug cost

$1,043,125

Median for Neurology: $202,670

Branded share of claims

38.2%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Kesimpta Pen Ofatumumab Brand 46 $412,274
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 24 $340,336
Ingrezza Valbenazine Tosylate Brand 14 $107,569
Aptiom Eslicarbazepine Acetate Brand 24 $48,361
Rytary Carbidopa/Levodopa Brand 26 $38,525
Fycompa Perampanel Brand 25 $30,072
Vimpat Lacosamide Brand 13 $15,127
Carbidopa-Levodopa Carbidopa/Levodopa Brand 213 $7,226
Modafinil Generic 18 $7,058
Lacosamide Generic 21 $3,607

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$337,758

Of which drugs: $280,852

Medicare patients

413

Average age 73

Services billed

25,780

210 women, 203 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Depression 36%
Diabetes 30%
Ischemic heart disease 29%
Chronic kidney disease 24%
Atrial fibrillation 22%
Alzheimer's or dementia 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 22 9,600 $44,955
Injection, gadoterate meglumine, 0.1 ml A9575 Office 51 8,780 $814

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FYCOMPA
  • CATALYST PHARMACEUTICALS, INC. $122
$122 25 —
Epidiolex
  • JAZZ PHARMACEUTICALS INC. $119
$119 — —
VYEPTI
  • Lundbeck LLC $46
$46 — —
Briviact
  • UCB, Inc. $32
$32 — —
VYVGART Hytrulo
  • ARGENX US, INC. $26
$26 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

141 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record